Osteocalcin (bone remodeling marker)
Conduct this analysis
Blood draws at our service locations in Quebec. A healthcare professional can also review your results with you.
Biology and pre-analytics
- Synthesis and secretion : synthesis exclusively by mature osteoblasts + carboxylation of Gla residues is vitamin K-dependent → vitamin K deficiency produces undercarboxylated osteocalcin (ucOC) which is released into the circulation without bone incorporation + circulating fraction: intact OC (whole molecule) + N-terminal mid fragments (main fragments detected by immunoassays) + short serum half-life: 20-30 minutes for intact osteocalcin + accumulation in renal tubules → renal failure increases serum osteocalcin concentrations independently of bone remodeling
- Circadian and seasonal variations : marked circadian rhythm - nocturnal peak (around 4-6 a.m.) + mid-afternoon nadir → daily variation of 15-30 % → standardized sampling recommended: morning on an empty stomach + between 8 and 10 a.m. + after at least 30 minutes' rest + same time at each check + seasonal variation: higher values in winter (vitamin D deficiency) + lower in summer
- Pre-analytical stability - osteocalcin's weak point : osteocalcin is highly sensitive to proteolytic degradation + unstable at room temperature (loses 50 % of its activity in 24 hours at 4°C) + the sample must be centrifuged quickly + the serum separated + frozen at -20°C or -80°C if the assay is delayed + transported on ice → it is precisely this preanalytical instability that limits its practical use compared with P1NP (stable for several days at 4°C) and CTX (stable at -20°C)
- Dosage methods : immunoassays (ELISA + RIA + ECLIA + CLIA) using antibodies directed against different epitopes of the molecule → results are not interchangeable between laboratories using different kits → important to always follow the same patient with the same method in the same laboratory
Reference values
| Population | Usual serum osteocalcin values | Remarks |
|---|---|---|
| Pre-menopausal women (18-50 years) | 11 to 43 µg/L (ng/mL) | Most stable values in adult female life + menstrual cycle slightly influences values (slight rise in follicular phase) |
| Post-menopausal women (aged 50-65) | 15 to 46 µg/L | Increase often marked in the first 5 years post-menopause (activation of bone remodelling by estrogen deficiency) + gradually decreases after age 65-70 |
| Elderly women (> 70 years) | 12 to 55 µg/L | Wider variability + delicate interpretation due to frequent relative renal failure and multiple comorbidities |
| Adult men (25-70 years) | 14 to 42 µg/L | Values slightly higher than in premenopausal women + gradual decrease with age after 50-60 years |
| Children and teenagers | 50 to 150 µg/L or more depending on age | Very high values during bone growth (up to 5-10 times adult values at pubertal peak) → always interpret according to age-specific paediatric standards |
| Unit note | Results can be expressed in µg/L = ng/mL = nmol/L (conversion factor: 1 µg/L ≈ 0.167 nmol/L for PM 5,800 Da human osteocalcin) + check the unit reported by the laboratory before interpretation | |
Causes of elevated osteocalcin
| Clinical situation | Mechanism | Context and elevation |
|---|---|---|
| Menopause and estrogen deficiency | Falling estrogen lifts its inhibition on osteoclasts → activation of bone remodeling → coupled increase in resorption AND formation (formation markers rise in response to osteoclastic activation) → elevation of osteocalcin in the first 5-10 years post-menopause | Moderate to significant elevation (sometimes doubling pre-menopausal values) + signal predictive of accelerated bone loss + very high osteocalcin in early post-menopause is an independent fracture risk factor |
| Primary hyperparathyroidism | Excess PTH → direct stimulation of bone formation and resorption → elevation of all bone remodelling markers including osteocalcin | Elevation often moderate in asymptomatic forms + significant in forms with clinical bone involvement (osteitis fibrocystica) + to be corrected with surgical treatment (parathyroidectomy) |
| Bone Paget's disease | Anarchic and locally accelerated bone remodeling → massive osteoblastic hyperactivity → very significant elevation of bone formation and resorption markers | Major elevation (often 5 to 10 times normal) + correlates with extent of disease + bone alkaline phosphatase also very high + very high CTX (coupled resorption) |
| Fracture healing | Intense activation of osteoblasts during bone callus formation → transient elevation of osteocalcin in the weeks following a fracture | Transient elevation for 6 to 12 weeks + returns to normal once consolidation is complete + may interfere with interpretation if assayed shortly after fracture |
| Hyperthyroidism | Thyroid hormones directly stimulate osteoblasts and osteoclasts → activation of remodeling + accelerated bone loss + elevation of formation and resorption markers | Elevation proportional to severity of hyperthyroidism + normalization after treatment of hyperthyroidism (often within a few months) |
| Childhood and adolescence | Active bone growth → physiological osteoblastic hyperactivity → very high values normal throughout the growth period | Values normal for age but much higher than adult norms + peak at time of pubertal acceleration + always use appropriate paediatric norms |
Causes of low osteocalcin
- Systemic corticosteroid therapy : main drug responsible for low osteocalcin + glucocorticoids directly inhibit osteocalcin gene transcription in osteoblasts → rapid reduction in osteocalcin synthesis from the first weeks of treatment → low osteocalcin on corticosteroids reflects inhibition of bone formation responsible for cortisone-induced osteoporosis + suppression is dose-dependent and reversible + interest in osteocalcin monitoring in cortisone-induced osteoporosisdependent and reversible on discontinuation of treatment + osteocalcin is useful for monitoring cortisone-induced osteoporosis
- Bisphosphonates and denosumab: bisphosphonates (alendronate + risedronate + zoledronic acid) inhibit osteoclastic resorption → bone coupling → secondary reduction in bone formation → decrease in osteocalcin (and P1NP) from 40 to 70 % after 3 to 6 months of treatment → suppression of formation markers under bisphosphonates confirms efficacy of anti-resorptive therapy
- Hypoparathyroidism: PTH deficiency → reduced bone remodeling → decreased bone formation and resorption → low osteocalcin + low blood calcium + high blood phosphorus (typical workup)
- Severe hypothyroidism : overall slowdown in metabolism, including bone remodelling → decrease in formation and resorption markers + normalization after hormone replacement therapy
- Type 2 diabetes: recent data suggest that under-carboxylated osteocalcin (ucOC) is lower in patients with type 2 diabetes + obesity - this deficit may contribute to insulin resistance (see hormonal functions of osteocalcin) + total osteocalcin is also lowered in type 2 diabetes probably through high insulin levels inhibiting osteocalcin secretion
Osteocalcin and extraosseous hormonal functions
- Regulation of blood sugar and energy metabolism : work by Gerard Karsenty (Columbia University - Cell 2007) → under-carboxylated osteocalcin (ucOC) acts as an endocrine hormone + stimulates insulin secretion by pancreatic beta cells + improves insulin sensitivity in muscle and adipose tissue + increases energy expenditure + in mice, osteocalcin gene invalidation induces type 2 diabetes and obesity + clinical relevance in humans still under evaluation, but several epidemiological studies associate low osteocalcin with an increased risk of type 2 diabetes and metabolic syndrome
- Male fertility: osteocalcin stimulates testosterone production by testicular Leydig cells via a specific receptor (GPRC6A) + promotes spermatogenesis + in male mice with inactivated osteocalcin receptors → hypogonadism and infertility + potential link with male hypogonadism associated with osteoporosis in aging men
- Cognition and memory : osteocalcin crosses the blood-brain barrier + stimulates synthesis of cerebral monoamines (dopamine + serotonin + noradrenaline) + improves memory performance in mouse models + plasma osteocalcin declines with age + may contribute to age-related cognitive decline + human studies underway
- Current clinical note : these hormonal functions are well-established in mice, but clinical transposition to humans has yet to be formally confirmed by clinical trials + osteocalcin is not yet used as a biomarker or therapeutic target for these indications in standard clinical practice
Osteocalcin versus P1NP and CTX - which bone marker to use?
- P1NP (N-terminal propeptide of type I procollagen) - preferential marker of bone formation: recommended by IOF + IFCC + Osteoporosis Canada as a reference marker of bone formation in the monitoring of osteoporosis + better pre-analytical stability than osteocalcin + lower biological variability + assay in serum or plasma + stable for 24 h at room temperature + superior to osteocalcin for monitoring anti-osteoporosis treatment + recommended as first-line treatment
- CTX (C-terminal cross-linking telopeptide of type I collagen) - preferential marker of bone resorption: recommended by the IOF + IFCC as a reference marker of bone resorption + morning fasting serum assay (very marked circadian variation - 30-40 % depending on the time of day) + reflection of osteoclastic activity + most widely used in practice for monitoring bisphosphonates and denosumab
- Osteocalcin - when should it still be prescribed? : global assessment of bone remodelling as a complement to P1NP and CTX + search for severe suppression of bone remodelling on bisphosphonates (very low osteocalcin = excessive suppression of remodelling → theoretical risk of atypical fracture) + research context (endocrine functions) + situations where P1NP is not available locally + assessment of cortisone-induced osteoporosis
A very high or very low osteocalcin result discovered by chance must be interpreted in the clinical context by a physician - it can never be interpreted in isolation. A very high osteocalcin result may indicate undiagnosed hyperparathyroidism, Paget's disease, hyperthyroidism or early menopause - conditions that warrant a full work-up and treatment. Low osteocalcin in a patient on corticosteroids without bone supplementation or densitometric assessment should lead to the prescription of DXA and consideration of preventive anti-osteoporotic treatment.
For bone metabolism assessments including osteocalcin, P1NP, CTX, calcium, vitamin D and DXA as part of osteoporosis follow-up or in cases of suspected bone disease, Clinique Omicron offers medical consultations at its points of service in Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
Consult at Clinique Omicron
Clinique Omicron's specialized physicians and nurse practitioners (SPNs) prescribe and interpret bone remodeling markers (osteocalcin + P1NP + CTX) as part of osteoporosis assessment, follow-up of anti-osteoporosis treatment, monitoring of cortisone-induced osteoporosis and investigation of hypercalcemia or metabolic bone disease. Consultations are available at several points of service in Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
The contents of this page are provided for information purposes only and do not replace the advice of a physician, rheumatologist or endocrinologist. Interpretation of bone remodeling markers must always be integrated into the overall clinical context (age + gender + current treatments + comorbidities) and cannot be performed in isolation.
Omicron Clinic
Need to consult a doctor?
In-person or via telemedicine, anywhere in Quebec.
We accept insurance. Telemedicine consultations available 7 days a week. No family doctor required.